Entry |
|
Name |
Tyrosine kinase inhibitor to HER2 overexpression/amplification
|
Definition |
(Trastuzumab,Trastuzumab_emtansine,Pertuzumab,Lapatinib,Neratinib,Tucatinib,Margetuximab) -| (ERBB2*,ERBB2*) |
Expanded |
(D03257,D09980,D05446,D04024,D10898,D11141,D10446) -| (2064v1,2064v3) |
Type |
Drug target
|
Gene |
2064 | ERBB2; erb-b2 receptor tyrosine kinase 2 |
|
Variant |
|
Perturbant |
|
Reference |
|
Authors |
Nahta R, Hung MC, Esteva FJ |
Title |
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. |
Journal |
|
Reference |
|
Authors |
LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX |
Title |
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. |
Journal |
|
LinkDB |
|